Skip to main content
OpenTrials
Completed

NCT Number: NCT04098549

The Effect of Rapid and Slow Glucose Fall on the Subsequent Glucose Production in People With Type 1 Diabetes

In the effort of better understanding the glucose control in people with type 1 diabetes, in-depth insight into the physiology of hepatic glucose production and its influencing factors is essential. Previously, a number of potential influencing factors of hepatic glucose production have been investigated, including insulin-on-board, low carbohydrate diet, preceding ethanol intake, exercise and multiple stimulations of hepatic glucose production. Previous post-hoc analysis of dual-hormone closed-loop systems has indicated that the rate of fall in blood glucose influences the following stimulation of hepatic glucose response. However, the rate of fall in blood glucose is highly related to insulin levels, which may explain those findings. Thus, in this study the investigators want to examine whether the different rates of fall in blood glucose with similar insulin levels on board affect the hepatic glucose response in individuals with type 1 diabetes. In the study, which will be conducted at Steno Diabetes Center Copenhagen, participants will complete two study visits. On each visit, a hypoglycemic clamp technique will be used to lower the blood glucose levels of the participants (using either a rapid or slow decline rate), whereupon hepatic glucose production will be stimulated using low-dose glucagon. The study days are divided into four phases: 1) preparation phase, 2) hyperinsulinemic euglycemic phase (stabilization of blood glucose), 3) hyperinsulinemic hypoglycemic phase (rapid or slow decline in blood glucose) and 4) post-glucagon administration phase. This design will allow the investigators to examine whether differences in hepatic glucose response exist depending on preceding rate of fall in blood glucose. We hypothesize that the rate of fall in blood glucose does not affect the hepatic glucose production.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Steno Diabetes Center Copenhagen

Gentofte Municipality, 2820, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-70 years
  • Duration of Type 1 Diabetes ≥ 3 years
  • Insulin pump use > 6 months

Exclusion criteria

  • Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
  • Allergy or intolerance to lactose or GlucaGen (Novo Nordisk, Bagsværd, DK)
  • Use of medications that are known to cause QT interval prolongation
  • Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
  • Females who have different basal insulin pattern depending on their menstrual cycle
  • Inability to understand the individual information and to give informed consent
  • Current participation in another clinical trial that, in the judgment of the principle investigator, will compromise the results of the study or the safety of the subject
  • Other concomitant medical or psychological condition that according to the investigator's assessment makes the individual unsuitable for study participation

Treatment and study plan

Rapid lowering of plasma glucose

Other

Rapid lowering of plasma glucose using hypoglycemic clamp technique

Slow lowering of plasma glucose

Other

Slow lowering of plasma glucose using hypoglycemic clamp technique

Primary outcomes

  1. Positive incremental area under the glucose curve (PI-AUC) (using the plasma glucose concentration before glucagon administration as basal level)

    Time frame: from 0-120 minutes after glucagon administration

Secondary outcomes

  1. Total area under the glucose curve (AUC)

    Time frame: from 0-120 minutes after glucagon administration

  2. Peak plasma glucose

    Time frame: from 0-120 minutes after glucagon administration

  3. Incremental plasma glucose peak

    Time frame: from 0-120 minutes after glucagon administration

  4. Time-to-peak plasma glucose

    Time frame: from 0-120 minutes after glucagon administration

  5. Plasma glucose level

    Time frame: 120 minutes after glucagon administration

  6. Duration of plasma glucose above 4.0 mmol/l

    Time frame: from 0-120 minutes after glucagon administration

  7. Duration of plasma glucose above baseline

    Time frame: from 0-120 minutes after glucagon administration

  8. Number of subjects who, after reaching a plasma glucose value > 3.9 mmol/l following glucagon administration, maintain a plasma glucose level in the range of 3.9-10 mmol/l

    Time frame: throughout phase 4 (until 120 minutes after glucagon administration)

  9. Number of subjects who, after reaching a PG > 3.9 mmol/l following glucagon administration, maintain a plasma glucose level in the range of 3.9-7.8 mmol/l

    Time frame: throughout phase 4 (until 120 minutes after glucagon administration)

  10. Time from glucagon administration to reaching a plasma glucose level > 3,9 mmol/l

    Time frame: from 0-120 minutes after glucagon administration

  11. Duration of a plasma glucose level in the range of 3.9-10 mmol/l

    Time frame: from 0-120 minutes after glucagon administration

  12. Duration of a plasma glucose level in the range of 3.9-7.8 mmol/l

    Time frame: from 0-120 minutes after glucagon administration

  13. Change in insulin levels (measured as area under the curve)

    Time frame: 0-120 minutes after glucagon administration

  14. Change in insulin levels (measured as peak change)

    Time frame: from baseline to 120 minutes after glucagon administration

  15. Change in glucagon levels (measured as area under the curve)

    Time frame: 0-120 minutes after glucagon administration

  16. Change in glucagon levels (measured as peak change)

    Time frame: 0-120 minutes after glucagon administration

  17. Average changes in Edinburgh Hypoglycemia Scale

    Time frame: measured at baseline, 5 minutes prior to the end of phase 2, 5 minutes prior to the end of phase 3 and 30 and 115 minutes after glucagon administration

  18. Average change in visual analogue scale score for nausea, headache, stomach ache and palpitations

    Time frame: measured at baseline, 5 minutes prior to the end of phase 2, 5 minutes prior to the end of phase 3 and 30 and 115 minutes after glucagon administration

  19. Number of subjects experiencing vomiting

    Time frame: from 0-120 minutes after glucagon administration

Sponsors and collaborators

Lead sponsor

Steno Diabetes Center Copenhagen

Other

Collaborators

  • University of Copenhagen

Registry information

Acronym: RaSlo-19

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Sep 23, 2019
Registry last updated
Jun 25, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.